Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffaele Giusti

Showing results (101-110 of 138) with videos related to

Pageof 14
Sort By:
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse eventsAlessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
Cancer Letters|June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort studyKylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
Journal for Immunotherapy of Cancer|November 6, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceAlessio Cortellini, Marco Tucci, Vincenzo Adamo, et al.
Journal for Immunotherapy of Cancer|May 21, 2021
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
The Oncologist|February 24, 2019
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse StudyAlessio Cortellini, Sebastiano Buti, Daniele Santini, et al.
Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.
Cancer Treatment and Research Communications|February 26, 2026
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational studyPaolo Bironzo, Alessandro Morabito, Sonia Silipigni, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Journal for Immunotherapy of Cancer|March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Pageof 14

Showing results (101-110 of 138) with videos related to

Sort By:
Pageof 14
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse eventsAlessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
Cancer Letters|June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort studyKylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
Journal for Immunotherapy of Cancer|November 6, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceAlessio Cortellini, Marco Tucci, Vincenzo Adamo, et al.
Journal for Immunotherapy of Cancer|May 21, 2021
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
The Oncologist|February 24, 2019
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse StudyAlessio Cortellini, Sebastiano Buti, Daniele Santini, et al.
Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.
Cancer Treatment and Research Communications|February 26, 2026
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational studyPaolo Bironzo, Alessandro Morabito, Sonia Silipigni, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Journal for Immunotherapy of Cancer|March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorableAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Pageof 14